Compass Therapeutics Stock Market Value
| CMPX Stock | USD 6.16 0.25 3.90% |
| Symbol | Compass |
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Compass Therapeutics. Projected growth potential of Compass fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Compass Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Compass Therapeutics is measured differently than its book value, which is the value of Compass that is recorded on the company's balance sheet. Investors also form their own opinion of Compass Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Compass Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Compass Therapeutics' market value can be influenced by many factors that don't directly affect Compass Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Compass Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Compass Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Compass Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Compass Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Compass Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Compass Therapeutics.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Compass Therapeutics on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Compass Therapeutics or generate 0.0% return on investment in Compass Therapeutics over 90 days. Compass Therapeutics is related to or competes with Fulcrum Therapeutics, 4D Molecular, Ocugen, Bicycle Therapeutics, Gossamer Bio, Lexicon Pharmaceuticals, and Monopar Therapeutics. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-... More
Compass Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Compass Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Compass Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.5 | |||
| Information Ratio | 0.215 | |||
| Maximum Drawdown | 16.9 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 7.61 |
Compass Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compass Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Compass Therapeutics' standard deviation. In reality, there are many statistical measures that can use Compass Therapeutics historical prices to predict the future Compass Therapeutics' volatility.| Risk Adjusted Performance | 0.1755 | |||
| Jensen Alpha | 0.871 | |||
| Total Risk Alpha | 0.6215 | |||
| Sortino Ratio | 0.2427 | |||
| Treynor Ratio | 1.56 |
Compass Therapeutics January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1755 | |||
| Market Risk Adjusted Performance | 1.57 | |||
| Mean Deviation | 3.1 | |||
| Semi Deviation | 2.79 | |||
| Downside Deviation | 3.5 | |||
| Coefficient Of Variation | 433.85 | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.61 | |||
| Information Ratio | 0.215 | |||
| Jensen Alpha | 0.871 | |||
| Total Risk Alpha | 0.6215 | |||
| Sortino Ratio | 0.2427 | |||
| Treynor Ratio | 1.56 | |||
| Maximum Drawdown | 16.9 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 7.61 | |||
| Downside Variance | 12.25 | |||
| Semi Variance | 7.81 | |||
| Expected Short fall | (3.68) | |||
| Skewness | 0.3373 | |||
| Kurtosis | (0.35) |
Compass Therapeutics Backtested Returns
Compass Therapeutics appears to be moderately volatile, given 3 months investment horizon. Compass Therapeutics secures Sharpe Ratio (or Efficiency) of 0.23, which signifies that the company had a 0.23 % return per unit of risk over the last 3 months. By analyzing Compass Therapeutics' technical indicators, you can evaluate if the expected return of 0.91% is justified by implied risk. Please makes use of Compass Therapeutics' Downside Deviation of 3.5, mean deviation of 3.1, and Risk Adjusted Performance of 0.1755 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Compass Therapeutics holds a performance score of 18. The firm shows a Beta (market volatility) of 0.58, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Compass Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Compass Therapeutics is expected to be smaller as well. Please check Compass Therapeutics' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Compass Therapeutics' price patterns will revert.
Auto-correlation | 0.65 |
Good predictability
Compass Therapeutics has good predictability. Overlapping area represents the amount of predictability between Compass Therapeutics time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Compass Therapeutics price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Compass Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.2 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.